NHC Key Laboratory of Systems Biology of Pathogens (Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College), Beijing 100730, P.R. China.
NHC Key Laboratory of Systems Biology of Pathogens (Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College), Beijing 100730, P.R. China.
Int J Oncol. 2020 Nov;57(5):1116-1128. doi: 10.3892/ijo.2020.5125. Epub 2020 Sep 22.
Progressive liver fibrosis, caused by chronic viral infection and metabolic disorders, results in the development of cirrhosis and hepatocellular carcinoma. However, no antifibrotic therapies have been approved to date. In our previous study, adeno‑associated virus (AAV) short hairpin RNAs (shRNAs) targeting hepatitis B virus (HBV) and transforming growth factor (TGF)‑β administration could persistently inhibit HBV replication and concomitantly prevent liver fibrosis. However, the differentially expressed proteins and critical regulatory networks of AAV‑shRNA treatment remain unclear. Accordingly, in the present study, we aimed to analyze differentially expressed proteins in the liver of AAV‑shRNA‑treated mice with HBV infection and liver fibrosis using isobaric tags for relative and absolute quantitation (iTRAQ)‑based quantitative proteomics and to elucidate the underlying antifibrotic mechanisms. In total 2,743 proteins were recognized by iTRAQ‑based quantitative proteomics analysis. Gene Ontology analysis revealed that the differentially expressed proteins mostly participated in peptide metabolism in the biological process category, cytosolic ribosomes in the cell component category, and structural constituents of ribosomes in the molecular function category. Kyoto Encyclopedia of Genes and Genomes pathway analysis indicated that oxidative stress and the peroxisome proliferator‑activated receptor (PPAR) signaling pathway were activated after treatment. Verification studies revealed that AAV‑shRNAs inhibited hepatic stellate cell activation and inflammation by suppressing nuclear factor‑κB p65 phosphorylation and α‑smooth muscle actin expression via upregulation of PPAR‑γ. Hepatocytes steatosis was also decreased by activating the PPAR signaling pathway and improving lipid metabolism. The expression level of TGF‑β was decreased due to upregulation of PPAR‑γ expression and direct inhibition using AAV‑shRNA targeting TGF‑β. TGF‑β‑induced oxidative stress was suppressed by increasing glutathione S‑transferase Pi 1 and reducing peroxiredoxin 1. Collectively, the present results indicated that AAV‑shRNAs were effective in modulating liver fibrosis by reducing oxidative stress, inflammation and activating the PPAR signaling pathway.
慢性病毒感染和代谢紊乱导致进行性肝纤维化,进而发展为肝硬化和肝细胞癌。然而,迄今为止尚无抗纤维化疗法获得批准。在我们之前的研究中,腺相关病毒(AAV)短发夹 RNA(shRNA)靶向乙型肝炎病毒(HBV)和转化生长因子(TGF)-β给药可持续抑制 HBV 复制,并同时预防肝纤维化。然而,AAV-shRNA 治疗的差异表达蛋白和关键调控网络仍不清楚。因此,本研究旨在通过基于同位素标记相对和绝对定量(iTRAQ)的定量蛋白质组学分析,研究 AAV-shRNA 治疗 HBV 感染和肝纤维化小鼠的肝脏中差异表达的蛋白质,并阐明其潜在的抗纤维化机制。iTRAQ 基于定量蛋白质组学分析共鉴定到 2743 种蛋白质。基因本体论分析显示,差异表达的蛋白质主要参与生物过程分类中的肽代谢、细胞成分分类中的胞质核糖体和分子功能分类中的核糖体结构成分。京都基因与基因组百科全书通路分析表明,治疗后氧化应激和过氧化物酶体增殖物激活受体(PPAR)信号通路被激活。验证研究表明,AAV-shRNA 通过抑制核因子-κB p65 磷酸化和α-平滑肌肌动蛋白表达,上调 PPAR-γ,抑制肝星状细胞激活和炎症。通过激活 PPAR 信号通路和改善脂质代谢,也减少了肝细胞脂肪变性。通过上调 PPAR-γ 表达和使用靶向 TGF-β 的 AAV-shRNA 直接抑制,TGF-β 的表达水平降低。通过增加谷胱甘肽 S-转移酶 Pi1 和减少过氧化物酶 1,抑制 TGF-β 诱导的氧化应激。综上所述,本研究结果表明,AAV-shRNA 通过降低氧化应激、炎症和激活 PPAR 信号通路,有效调节肝纤维化。